仙蟾片联合化疗方案治疗老年食管癌患者的临床研究

Clinical study of Xianchan Tablets combined with chemotherapy in the treatment of elderly patients with esophageal cancer

  • 摘要: 目的 探讨仙蟾片配合化疗方案治疗老年食管癌患者的临床效果。 方法 选取68例老年食管癌患者作为研究对象,采用数字随机分组法分为对照组与观察组,各34例。对照组采用一般化疗方案治疗,观察组采用仙蟾片联合化疗方案治疗,比较2组患者的治疗效果。 结果 观察组的治疗有效率为91.2%, 高于对照组70.6%, 差异有统计学意义(P < 0.05); 治疗后, 2组间免疫球蛋白A(IgA)、CD3+、神经原特异性烯醇化酶(NSE)、癌胚抗原(CEA)指标水平比较,差异有统计学意义(P < 0.05); 治疗后3个月内随访,观察组患者生活质量评分高于对照组,差异有统计学意义(P < 0.05); 治疗后,观察组不良反应发生率为14.7%, 对照组为11.8%, 差异无统计学意义(P > 0.05)。 结论 仙蟾片配合化疗方案治疗老年食管癌患者疗效显著,可改善血清肿瘤标志物、免疫功能指标水平,且不会增加不良反应。

     

    Abstract: Objective To analyze the effect of Xianchan Tablets combined with chemotherapy in treatment of elderly patients with esophageal cancer. Methods Sixty-eight elderly patients with esophageal cancer treated in the hospital were selected by digital random grouping, including 34 cases in the control group and 34 cases in the observation group. The control group was treated with general chemotherapy regimen, while the observation group was given Xianchan Tablets combined with chemotherapy. The treatment effects of the two groups were observed and compared. Results The treatment response rate was higher in the observation group than that in the control group, and the difference was statistically significant(91.2% vs. 70.6%, P < 0.05). After treatment, the immunoglobulin A(IgA), CD3+, neuron specific enolase(NSE), carcinoembryonic antigen(CEA)indexes of two groups showed significant differences(P < 0.05). Follow-up within 3 months after treatment showed that there was a significant difference in the quality of life score between the observation group and the control group(P < 0.05). The incidence of adverse reactions after treatment was 14.7% in the observation group and 11.8% in the control group, but no significant difference between the two groups was observed(P > 0.05). Conclusion Chemotherapy combined with Xianchan Tablets has significant efficacy in the clinical treatment of elderly patients with esophageal cancer, which can improve serum tumor markers and immune function indicators, without adverse reactions increasing.

     

/

返回文章
返回